ANDA-Evaluating Facilitated Feedback Enhancement - a Cluster randomised Trial (ANDA-EFFECT): protocol for a cluster randomised trial of audit feedback augmented with education and support, compared to feedback alone, on acceptability, utility and health outcomes in diabetes centres in Australia.
Audit and feedback
Cluster randomised trial
Diabetes mellitus
Educational
Feedback intervention
Peer support
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
05 Dec 2022
05 Dec 2022
Historique:
received:
07
09
2021
accepted:
10
11
2022
entrez:
6
12
2022
pubmed:
7
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
People living with diabetes must manage a range of factors for optimal control of glycaemia and to minimise the risk of diabetes-related complications. Diabetes practitioners are expected to follow guidelines for the key process of care and clinical outcomes, to help people living with diabetes achieve clinical targets. In Australia, the performance of diabetes centres against guidelines is evaluated by the Australian National Diabetes Audit, an annual clinical audit and feedback activity. Previous work has identified areas for improvement in the feedback provided to participating diabetes centres and suggested additional educational and support resources to assist in using audit feedback for the development of quality improvement activities. This cluster randomised trial will test the acceptability, utility and impact on selected clinical outcomes of the developed study intervention (audit feedback and a tailored educational and peer support cointervention). Two-armed cluster randomised trial with Australian Diabetes Centres that participated in the Australian National Diabetes Audit in 2021 as the clusters, stratified by location and type of centre. We aim to recruit 35 diabetes centres in each arm. Both the intervention and control arms will receive an augmented feedback report, accompanied by a partially pre-populated slide deck. In addition, the intervention arm will receive a tailored theory-based intervention designed to address identified, modifiable barriers to utilising and implementing the recommendations from diabetes audit feedback. The co-primary outcomes are (1) HbA1c at the patient level, measured at 6 months after delivery of the intervention, and (2) the acceptability and utility of the augmented feedback and cointerventions at the practitioner level, measured at 3 months after delivery of the intervention. This trial aims to test the effects of systematic development and implementation of theory and evidence-informed changes to the audit feedback delivered to diabetes centres participating in an established national clinical diabetes audit. Potential benefits of improved audit feedback include more optimal engagement with the feedback by end clinical users which, ultimately, may lead to improvements in care for people living with diabetes. Australian and New Zealand Clinical Trials Registry ACTRN12621000765820. Prospectively registered on June 21, 2021.
Sections du résumé
BACKGROUND
BACKGROUND
People living with diabetes must manage a range of factors for optimal control of glycaemia and to minimise the risk of diabetes-related complications. Diabetes practitioners are expected to follow guidelines for the key process of care and clinical outcomes, to help people living with diabetes achieve clinical targets. In Australia, the performance of diabetes centres against guidelines is evaluated by the Australian National Diabetes Audit, an annual clinical audit and feedback activity. Previous work has identified areas for improvement in the feedback provided to participating diabetes centres and suggested additional educational and support resources to assist in using audit feedback for the development of quality improvement activities. This cluster randomised trial will test the acceptability, utility and impact on selected clinical outcomes of the developed study intervention (audit feedback and a tailored educational and peer support cointervention).
METHODS
METHODS
Two-armed cluster randomised trial with Australian Diabetes Centres that participated in the Australian National Diabetes Audit in 2021 as the clusters, stratified by location and type of centre. We aim to recruit 35 diabetes centres in each arm. Both the intervention and control arms will receive an augmented feedback report, accompanied by a partially pre-populated slide deck. In addition, the intervention arm will receive a tailored theory-based intervention designed to address identified, modifiable barriers to utilising and implementing the recommendations from diabetes audit feedback. The co-primary outcomes are (1) HbA1c at the patient level, measured at 6 months after delivery of the intervention, and (2) the acceptability and utility of the augmented feedback and cointerventions at the practitioner level, measured at 3 months after delivery of the intervention.
DISCUSSION
CONCLUSIONS
This trial aims to test the effects of systematic development and implementation of theory and evidence-informed changes to the audit feedback delivered to diabetes centres participating in an established national clinical diabetes audit. Potential benefits of improved audit feedback include more optimal engagement with the feedback by end clinical users which, ultimately, may lead to improvements in care for people living with diabetes.
TRIAL REGISTRATION
BACKGROUND
Australian and New Zealand Clinical Trials Registry ACTRN12621000765820. Prospectively registered on June 21, 2021.
Identifiants
pubmed: 36471424
doi: 10.1186/s13063-022-06910-9
pii: 10.1186/s13063-022-06910-9
pmc: PMC9720980
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
976Informations de copyright
© 2022. The Author(s).
Références
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):645-53
pubmed: 22851534
Diabetes Care. 2014;37(1):9-16
pubmed: 24356592
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Implement Sci. 2022 May 26;17(1):34
pubmed: 35619097
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
BMJ Open. 2013 Nov 15;3(11):e003555
pubmed: 24240140
Cardiovasc Diabetol. 2018 Jun 2;17(1):77
pubmed: 29859534
J Clin Epidemiol. 2003 Aug;56(8):730-5
pubmed: 12954464
Diabetes Care. 2021 Aug;44(8):e163-e164
pubmed: 34158364
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318
BMJ. 1998 Sep 12;317(7160):703-13
pubmed: 9732337
BMC Health Serv Res. 2022 Feb 24;22(1):255
pubmed: 35209903
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
BMJ Qual Saf. 2019 May;28(5):416-423
pubmed: 30852557
Diabetes Spectr. 2018 Aug;31(3):218-224
pubmed: 30140137
J Diabetes. 2021 Jan;13(1):78-88
pubmed: 32851797
BMJ Open. 2018 Aug 17;8(8):e020677
pubmed: 30121593
Diabetes Res Clin Pract. 2008 Apr;80(1):89-95
pubmed: 18160171